CA2477109C - System for transvaginal drug delivery - Google Patents
System for transvaginal drug delivery Download PDFInfo
- Publication number
- CA2477109C CA2477109C CA2477109A CA2477109A CA2477109C CA 2477109 C CA2477109 C CA 2477109C CA 2477109 A CA2477109 A CA 2477109A CA 2477109 A CA2477109 A CA 2477109A CA 2477109 C CA2477109 C CA 2477109C
- Authority
- CA
- Canada
- Prior art keywords
- delivery system
- drug
- tampon
- group
- outer layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000012377 drug delivery Methods 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 78
- 229940079593 drug Drugs 0.000 claims abstract description 77
- 239000000463 material Substances 0.000 claims abstract description 25
- 239000002250 absorbent Substances 0.000 claims abstract description 22
- 230000002745 absorbent Effects 0.000 claims abstract description 22
- 230000008021 deposition Effects 0.000 claims abstract description 12
- 210000001215 vagina Anatomy 0.000 claims abstract description 12
- 239000000080 wetting agent Substances 0.000 claims abstract description 11
- 238000003780 insertion Methods 0.000 claims abstract description 3
- 230000037431 insertion Effects 0.000 claims abstract description 3
- 229960001680 ibuprofen Drugs 0.000 claims description 32
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 31
- 229920001903 high density polyethylene Polymers 0.000 claims description 23
- 239000004700 high-density polyethylene Substances 0.000 claims description 23
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 19
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 16
- 229960002009 naproxen Drugs 0.000 claims description 16
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 16
- -1 anti-prostaglandin Substances 0.000 claims description 14
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 13
- 239000005556 hormone Substances 0.000 claims description 9
- 229940088597 hormone Drugs 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 5
- 229940124549 vasodilator Drugs 0.000 claims description 5
- 239000003071 vasodilator agent Substances 0.000 claims description 5
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 4
- 239000000048 adrenergic agonist Substances 0.000 claims description 4
- 230000001548 androgenic effect Effects 0.000 claims description 4
- 229940111134 coxibs Drugs 0.000 claims description 4
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 4
- 239000003450 potassium channel blocker Substances 0.000 claims description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
- 239000000480 calcium channel blocker Substances 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 229960004194 lidocaine Drugs 0.000 claims description 3
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 2
- DLNAKYFPFYUBDR-HDICACEKSA-N (4-aminophenyl)-[(1s,5r)-7-benzyl-3,7-diazabicyclo[3.3.1]nonan-3-yl]methanone Chemical compound C1=CC(N)=CC=C1C(=O)N1C[C@@H](CN(CC=2C=CC=CC=2)C2)C[C@@H]2C1 DLNAKYFPFYUBDR-HDICACEKSA-N 0.000 claims description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims description 2
- ZMHOBBKJBYLXFR-BPNWFJGMSA-N 4-[(2r)-3-[ethyl(3-propylsulfinylpropyl)amino]-2-hydroxypropoxy]benzonitrile Chemical compound CCCS(=O)CCCN(CC)C[C@@H](O)COC1=CC=C(C#N)C=C1 ZMHOBBKJBYLXFR-BPNWFJGMSA-N 0.000 claims description 2
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims description 2
- MREBEPTUUMTTIA-PCLIKHOPSA-N Azimilide Chemical compound C1CN(C)CCN1CCCCN1C(=O)N(\N=C\C=2OC(=CC=2)C=2C=CC(Cl)=CC=2)CC1=O MREBEPTUUMTTIA-PCLIKHOPSA-N 0.000 claims description 2
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims description 2
- ALOBUEHUHMBRLE-UHFFFAOYSA-N Ibutilide Chemical compound CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ALOBUEHUHMBRLE-UHFFFAOYSA-N 0.000 claims description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims description 2
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000006 Nitroglycerin Substances 0.000 claims description 2
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 claims description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 2
- 229950003699 almokalant Drugs 0.000 claims description 2
- 229950005516 ambasilide Drugs 0.000 claims description 2
- QZNJPJDUBTYMRS-UHFFFAOYSA-M amfenac sodium hydrate Chemical compound O.[Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=CC=C1 QZNJPJDUBTYMRS-UHFFFAOYSA-M 0.000 claims description 2
- 230000003431 anti-prostaglandin Effects 0.000 claims description 2
- 229950001786 azimilide Drugs 0.000 claims description 2
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 claims description 2
- 229960003665 bepridil Drugs 0.000 claims description 2
- 229960003655 bromfenac Drugs 0.000 claims description 2
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003150 bupivacaine Drugs 0.000 claims description 2
- 229960000590 celecoxib Drugs 0.000 claims description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 2
- SZKQYDBPUCZLRX-UHFFFAOYSA-N chloroprocaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl SZKQYDBPUCZLRX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004166 diltiazem Drugs 0.000 claims description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 2
- 230000000142 dyskinetic effect Effects 0.000 claims description 2
- 229960005309 estradiol Drugs 0.000 claims description 2
- 229930182833 estradiol Natural products 0.000 claims description 2
- 229940011871 estrogen Drugs 0.000 claims description 2
- 239000000262 estrogen Substances 0.000 claims description 2
- 229960003976 etidocaine Drugs 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 229960003580 felodipine Drugs 0.000 claims description 2
- 229950005722 flosulide Drugs 0.000 claims description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 2
- 229960004053 ibutilide Drugs 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims description 2
- 229960000201 isosorbide dinitrate Drugs 0.000 claims description 2
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 claims description 2
- 229960003827 isosorbide mononitrate Drugs 0.000 claims description 2
- 229960004752 ketorolac Drugs 0.000 claims description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 2
- 239000003589 local anesthetic agent Substances 0.000 claims description 2
- 229960001929 meloxicam Drugs 0.000 claims description 2
- 229960002409 mepivacaine Drugs 0.000 claims description 2
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims description 2
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 claims description 2
- 230000004118 muscle contraction Effects 0.000 claims description 2
- CXJONBHNIJFARE-UHFFFAOYSA-N n-[6-(2,4-difluorophenoxy)-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=O)C=2C=C1OC1=CC=C(F)C=C1F CXJONBHNIJFARE-UHFFFAOYSA-N 0.000 claims description 2
- 229960004270 nabumetone Drugs 0.000 claims description 2
- 229960001783 nicardipine Drugs 0.000 claims description 2
- 229960001597 nifedipine Drugs 0.000 claims description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 2
- 229960000715 nimodipine Drugs 0.000 claims description 2
- 229960002657 orciprenaline Drugs 0.000 claims description 2
- 229960002895 phenylbutazone Drugs 0.000 claims description 2
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims description 2
- 229960002702 piroxicam Drugs 0.000 claims description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 2
- 229960001309 procaine hydrochloride Drugs 0.000 claims description 2
- 239000000583 progesterone congener Substances 0.000 claims description 2
- 239000002089 prostaglandin antagonist Substances 0.000 claims description 2
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 claims description 2
- 229960001634 ritodrine Drugs 0.000 claims description 2
- 229960002052 salbutamol Drugs 0.000 claims description 2
- KHYPYQZQJSBPIX-UHFFFAOYSA-N sematilide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(NS(C)(=O)=O)C=C1 KHYPYQZQJSBPIX-UHFFFAOYSA-N 0.000 claims description 2
- 229950008118 sematilide Drugs 0.000 claims description 2
- 210000002460 smooth muscle Anatomy 0.000 claims description 2
- 229960002370 sotalol Drugs 0.000 claims description 2
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 claims description 2
- 229960000894 sulindac Drugs 0.000 claims description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 2
- CTIRHWCPXYGDGF-HDICACEKSA-N tedisamil Chemical compound [H][C@]12CN(CC3CC3)C[C@]([H])(CN(CC3CC3)C1)C21CCCC1 CTIRHWCPXYGDGF-HDICACEKSA-N 0.000 claims description 2
- 229960002926 tedisamil Drugs 0.000 claims description 2
- 229960000195 terbutaline Drugs 0.000 claims description 2
- 229960003604 testosterone Drugs 0.000 claims description 2
- 229960002494 tetracaine hydrochloride Drugs 0.000 claims description 2
- 229960001722 verapamil Drugs 0.000 claims description 2
- 239000003098 androgen Substances 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 229940125422 potassium channel blocker Drugs 0.000 claims 2
- SRUISGSHWFJION-UHFFFAOYSA-N E-4031 Chemical compound CC1=CC=CC(CCN2CCC(CC2)C(=O)C=2C=CC(NS(C)(=O)=O)=CC=2)=N1 SRUISGSHWFJION-UHFFFAOYSA-N 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000000758 substrate Substances 0.000 description 17
- 239000012530 fluid Substances 0.000 description 16
- 238000009472 formulation Methods 0.000 description 16
- 238000010521 absorption reaction Methods 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 229940035676 analgesics Drugs 0.000 description 5
- 239000000730 antalgic agent Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 239000003433 contraceptive agent Substances 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000002175 menstrual effect Effects 0.000 description 3
- 230000005070 ripening Effects 0.000 description 3
- 230000001150 spermicidal effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000009958 sewing Methods 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000264091 Petrus Species 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 229920002596 Polyethylene Glycol 900 Polymers 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002807 Thiomer Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000012435 analytical chromatography Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010983 kinetics study Methods 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
- 229940044953 vaginal ring Drugs 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 239000000003 vaginal tablet Substances 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/20—Tampons, e.g. catamenial tampons; Accessories therefor
- A61F13/2051—Tampons, e.g. catamenial tampons; Accessories therefor characterised by the material or the structure of the inner absorbing core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/43—Hormones, e.g. dexamethasone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/14—Female reproductive, genital organs
- A61M2210/1475—Vagina
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Materials Engineering (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Absorbent Articles And Supports Therefor (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A transvaginal drug delivery system comprising: (a) a deposition comprising an effective amount of said drug and, optionally, a wetting agent; and (b) a polymeric support on which said deposition is deposited. Also disclosed is a catamenial tampon for insertion in a human vagina comprising: (a) an inner core comprising an absorbent material; (b) an outer layer comprising a liquid-permeable material; and (c) a delivery system according to the invention. A method of transvaginal drug delivery is also described.
Description
SYSTEM FOR TRANSVAGINAL DRUG DELIVERY
FIELD OF THE INVENTION
This invention relates to a system and method for transvaginal drug delivery.
BACKGROUND OF THE INVENTION
Transvaginal drug delivery is a well known means of administering drugs to a female (Woolfson, A.D., Malcolm, R.K. and Gallagher, R. (2000) Critical Reviews in Therapeutic Drug Carrier Systems 17:509-555). The transvaginal route has several advantages: (1) it is non-invasive; (2) the vagina consists of highly perfused tissue with a well-developed blood supply; (3) it avoids first-pass metabolism in the liver. The transvaginal route may be used both for local drug io treatment as well as systemic drug absorption.
Transvaginal drug delivery systems may be classified in two main groups:
those adapted from semisolid topical systems and those designed specifically for intravaginal use. Known systems include the following:
= Mucoadhesive gels and hydrogels. These are weakly crosslinked polymers which are able to swell in contact with water and spread onto the surface of mucus. These have been used for cervical ripening, spermicidal contraception, vaccination and treatment of vaginal infections;
= Vaginal tablets. They may be formulated with mucoadhesive polymers in order to increase intravaginal residence time. They have been used for cervical ripening, spermicidal contraception, pregnancy termination, analgesia and urge incontinence;
= Vaginal pessaries and suppositories. These are substances such as natural gums, fatty acids, alum and rock salts which were originally used by the ancient CONFIRMATION COPY
FIELD OF THE INVENTION
This invention relates to a system and method for transvaginal drug delivery.
BACKGROUND OF THE INVENTION
Transvaginal drug delivery is a well known means of administering drugs to a female (Woolfson, A.D., Malcolm, R.K. and Gallagher, R. (2000) Critical Reviews in Therapeutic Drug Carrier Systems 17:509-555). The transvaginal route has several advantages: (1) it is non-invasive; (2) the vagina consists of highly perfused tissue with a well-developed blood supply; (3) it avoids first-pass metabolism in the liver. The transvaginal route may be used both for local drug io treatment as well as systemic drug absorption.
Transvaginal drug delivery systems may be classified in two main groups:
those adapted from semisolid topical systems and those designed specifically for intravaginal use. Known systems include the following:
= Mucoadhesive gels and hydrogels. These are weakly crosslinked polymers which are able to swell in contact with water and spread onto the surface of mucus. These have been used for cervical ripening, spermicidal contraception, vaccination and treatment of vaginal infections;
= Vaginal tablets. They may be formulated with mucoadhesive polymers in order to increase intravaginal residence time. They have been used for cervical ripening, spermicidal contraception, pregnancy termination, analgesia and urge incontinence;
= Vaginal pessaries and suppositories. These are substances such as natural gums, fatty acids, alum and rock salts which were originally used by the ancient CONFIRMATION COPY
Egyptians as contraceptives. They have been used for cervical ripening, treatment of vaginal infections, pregnancy termination and progesterone therapy;
= Microspheres for the delivery of peptide and protein drugs;
= Intravaginal rings. These are torus-shaped polymeric devices designed to release one or more incorporated drugs in a controlled fashion. They have been used for steroidal and spermicidal contraception, and estrogen replacement therapy.
U.S. Patent No. 3,918,452 (Cornfeld) discloses vaginal sponges and/or 1o tampons impregnated with contraceptive compositions. The composition comprises microcapsules containing a contraceptive drug and which provide sustained release of the drug before, during and/or after coitus.
U.S. Patent No. 4,309,997 (Donald) discloses a medicated tampon in the form of a soft, porous foam ball of spherical configuration. The tampon is impregnated with a contraceptive drug and/or an antibiotic for control of venereal disease. The tampon is inserted into the vagina to cover the cervical area while permitting intercourse to take place.
U.S. Patent No. 5,201,326 (Kubicki et al) discloses a rod-shaped medical tampon for releasing an active substance. The tampon includes a core of compressed fibers and a cover surrounding the core and glued thereto, the cover comprising hardened collagen foam or hardened gelatin foam impregnated with a retardant, such as a fatty substance, including the dissolved active substance to be released. The active substance may be antibiotics, sulfonamides, antimycotics, fungicides or hormones.
U.S. Patent No. 5,417,224 (Petrus et al) discloses a tampon comprising a porous spherical member having an inner region configured radially within an outer region, a cord extending through a passage extending through the spherical member, a spermicide within the pores of the inner region and a lubricant within the pores of the outer region.
= Microspheres for the delivery of peptide and protein drugs;
= Intravaginal rings. These are torus-shaped polymeric devices designed to release one or more incorporated drugs in a controlled fashion. They have been used for steroidal and spermicidal contraception, and estrogen replacement therapy.
U.S. Patent No. 3,918,452 (Cornfeld) discloses vaginal sponges and/or 1o tampons impregnated with contraceptive compositions. The composition comprises microcapsules containing a contraceptive drug and which provide sustained release of the drug before, during and/or after coitus.
U.S. Patent No. 4,309,997 (Donald) discloses a medicated tampon in the form of a soft, porous foam ball of spherical configuration. The tampon is impregnated with a contraceptive drug and/or an antibiotic for control of venereal disease. The tampon is inserted into the vagina to cover the cervical area while permitting intercourse to take place.
U.S. Patent No. 5,201,326 (Kubicki et al) discloses a rod-shaped medical tampon for releasing an active substance. The tampon includes a core of compressed fibers and a cover surrounding the core and glued thereto, the cover comprising hardened collagen foam or hardened gelatin foam impregnated with a retardant, such as a fatty substance, including the dissolved active substance to be released. The active substance may be antibiotics, sulfonamides, antimycotics, fungicides or hormones.
U.S. Patent No. 5,417,224 (Petrus et al) discloses a tampon comprising a porous spherical member having an inner region configured radially within an outer region, a cord extending through a passage extending through the spherical member, a spermicide within the pores of the inner region and a lubricant within the pores of the outer region.
U.S. Patent No. 6,086,909 (Harrison et al) discloses devices and methods for the treatment of dysmenorrhea which comprise an intravaginal drug delivery system containing an appropriate pharmaceutical agent which is released into the vagina and absorbed through the vaginal mucosa via lymphatic and venous channels to the uterus. The drug delivery system may include a tampon device, vaginal ring, pessary, tablet, vaginal suppository, vaginal sponge, bioadhesive tablet, bioadhesive microparticle, cream, lotion, foam, ointment, solution or gel.
The system may additionally include a muco-adhesive agent and/or a penetration enhancer. In the case where the device is an absorbent vaginal tampon, one end of to the tampon has a means for delivering the pharmaceutical agent while the other end has means for conveying fluid discharged from the uterus (such as menses fluid) to the tampon, thereby preventing contact of the fluid with the agent.
Non-steroidal anti-inflammatory drugs (NSAID) are marketed worldwide as over the counter (OTC) analgesics and antipyretics, of which, the most commonly used are aminophen, aspirin, ibuprofen and naproxen.
The mechanism of most anti-inflammatory, antipyretic and analgesic effects of NSAIDs result from the inhibition of prostaglandin synthesis from arachidonic acid. The target of NSAID action is PGHS, which is the key rate-limiting enzyme in the production of prostanoids. This enzyme catalyzes the conversion of arachidonic acid to PGH2 via a two-step reaction mechanism involving sequential cyclooxygenase and peroxydase activities.
Generally, OTC analgesics are regarded as safe for the majority of patients.
However, adverse effects have been reported and are mainly associated with the oral administration of NSAIDs, occurring mostly in the gastrointestinal tract.
Dyspepsia appears to be the most common side effect, but serious adverse effects such as bleeding, ulceration and perforation can also occur. The potential of adverse renal effects have also been reported, although for some NSAIDs this relationship remains controversial. Most adverse renal effects, however, are reversible on prompt discontinuation of the analgesics.
The system may additionally include a muco-adhesive agent and/or a penetration enhancer. In the case where the device is an absorbent vaginal tampon, one end of to the tampon has a means for delivering the pharmaceutical agent while the other end has means for conveying fluid discharged from the uterus (such as menses fluid) to the tampon, thereby preventing contact of the fluid with the agent.
Non-steroidal anti-inflammatory drugs (NSAID) are marketed worldwide as over the counter (OTC) analgesics and antipyretics, of which, the most commonly used are aminophen, aspirin, ibuprofen and naproxen.
The mechanism of most anti-inflammatory, antipyretic and analgesic effects of NSAIDs result from the inhibition of prostaglandin synthesis from arachidonic acid. The target of NSAID action is PGHS, which is the key rate-limiting enzyme in the production of prostanoids. This enzyme catalyzes the conversion of arachidonic acid to PGH2 via a two-step reaction mechanism involving sequential cyclooxygenase and peroxydase activities.
Generally, OTC analgesics are regarded as safe for the majority of patients.
However, adverse effects have been reported and are mainly associated with the oral administration of NSAIDs, occurring mostly in the gastrointestinal tract.
Dyspepsia appears to be the most common side effect, but serious adverse effects such as bleeding, ulceration and perforation can also occur. The potential of adverse renal effects have also been reported, although for some NSAIDs this relationship remains controversial. Most adverse renal effects, however, are reversible on prompt discontinuation of the analgesics.
Numerous studies have dealt with the controlled release of NSAIDs from capsules, matrices, or gels. Colloidal liposomal carriers in an injectable 25%
poloxamer gel were used to investigate the release properties of ibuprofen.
Poloxamer gel was also used for the epidural injection of lidocaine and ibuprofen.
Biodegradable matrices such as poly lactic acid (PLA) were also used for the controlled release of analgesics. Gel-yielding egg albumin-based matrices were used to study drug release kinetics. Other sustained release formulations consisted of hydroxypropyl methylcellulose (HPMC) matrices or matrices of synthetic crosslinked polymeric resins, as for example crosslinked poly acrylic acid.
It is estimated that 30 to 50% of the women of childbearing age in the US, are affected by painful menstrual periods or dysmenorrhea and 10 to 15% of those women are incapacitated for 1 to 3 days each month. The chief symptom that women experience is spasmodic pain of the lower abdomen, which may radiate to the back and along the thighs.
The etiology of these symptoms has been determined to be related to the pharmacologic actions of prostaglandin E2 (PGE2) and prostaglandin Fla (PGF2a), which are formed from phospholipids of dead cell membranes in the menstruating uterus. PGE2 causes disaggregation of platelets and is a vasodilator, whereas PGF2a mediates or potentiates pain sensations and stimulates smooth muscle contraction.
NSAIDs are successful as analgesics in 77 to 80% of dysmenorrhea patients, ibuprofen, naproxen, or naproxen sodium being the usual initial choices.
SUMMARY OF THE INVENTION
It is an object of the invention to provide a novel delivery system for use with a feminine hygienic product, such as a tampon, to deliver a drug through the female vagina.
It is another object of the invention to provide a method of transvaginal drug delivery.
poloxamer gel were used to investigate the release properties of ibuprofen.
Poloxamer gel was also used for the epidural injection of lidocaine and ibuprofen.
Biodegradable matrices such as poly lactic acid (PLA) were also used for the controlled release of analgesics. Gel-yielding egg albumin-based matrices were used to study drug release kinetics. Other sustained release formulations consisted of hydroxypropyl methylcellulose (HPMC) matrices or matrices of synthetic crosslinked polymeric resins, as for example crosslinked poly acrylic acid.
It is estimated that 30 to 50% of the women of childbearing age in the US, are affected by painful menstrual periods or dysmenorrhea and 10 to 15% of those women are incapacitated for 1 to 3 days each month. The chief symptom that women experience is spasmodic pain of the lower abdomen, which may radiate to the back and along the thighs.
The etiology of these symptoms has been determined to be related to the pharmacologic actions of prostaglandin E2 (PGE2) and prostaglandin Fla (PGF2a), which are formed from phospholipids of dead cell membranes in the menstruating uterus. PGE2 causes disaggregation of platelets and is a vasodilator, whereas PGF2a mediates or potentiates pain sensations and stimulates smooth muscle contraction.
NSAIDs are successful as analgesics in 77 to 80% of dysmenorrhea patients, ibuprofen, naproxen, or naproxen sodium being the usual initial choices.
SUMMARY OF THE INVENTION
It is an object of the invention to provide a novel delivery system for use with a feminine hygienic product, such as a tampon, to deliver a drug through the female vagina.
It is another object of the invention to provide a method of transvaginal drug delivery.
In a first aspect of the invention, there is provided a transvaginal drug delivery system comprising:
(a) a deposition comprising an effective amount of the drug and, optionally, a wetting agent; and (b) a polymeric support on which the deposition is deposited.
In the present specification, the term "transvaginal" includes both local delivery to the vagina (intravaginal) as well as through the vagina to other target tissues in the body, including systemic effects.
The drug used in the delivery system of the invention may be any drug 1o which either is released and acts locally or which is absorbed through the vaginal mucosa to other locations in the body. Examples of such drugs include non-steroidal anti-inflammatory drugs (NSAID), anti-prostaglandins, prostaglandin inhibitors, COX-2 inhibitors, local anaesthetics, calcium channel blockers, potassium channel blockers, (3-adrenergic agonists, leukotriene blocking drugs, smooth muscle inhibitors, vasodilators, hormone replacement drugs, androgenic hormones and drugs capable of inhibiting dyskinetic muscle contraction.
Non-limiting examples of NSAIDs suitable for use in the method of the invention include Aspirin, Ibuprofen, Indoinethacin, Phenylbutazone, Bromfenac, Fenamate, Sulindac, Nabumetone, Ketorolac, and Naproxen. Examples of local anesthetics include Lidocaine, Mepivacaine, Etidocaine, Bupivacaine, 2-Chloroprocaine hydrochloride, Procaine, and Tetracaine hydrochloride.
Examples of calcium channel antagonists include Diltiazem, Israpidien, Nimodipine, Felodipine, Verapamil, Nifedipine, Nicardipine, and Bepridil. Examples of potassium channel blockers include Defetilide, E-403 1, Almokalant, Sematilide, Ambasilide, Azimilide, Tedisamil, RP58866, sotalol, Piroxicam, and Ibutilide.
Examples of p-adrenergic agonists include Terbutaline, Salbutamol, Metaproterenol, and Ritodrine. Vasodilators, which are believed to relieve muscle spasm in the uterine muscle, include nitroglycerin, isosorbide dinitrate and isosorbide mononitrate. Examples of COX-2 inhibitors are Celecoxib, Meloxicam and Flosulide. Examples of hormone replacement drugs are estrogen or estradiol and progestogen. Examples of androgenic hormones are testosterone and other androgenic hormones.
The drug may be present in the system in combination with a biocompatible excipient or carrier acceptable for application of the drug to the vaginal epithelium.
Although the mechanism may be diffusion-controlled, the co-inclusion of excipients such as wetting agents or surfactants in the formulation, may be necessary. The term "an effective amount" in this specification means an amount sufficient to attain a therapeutically effective amount of the drug in the target tissue or system. In a preferred embodiment, the drug is absorbable through the vaginal mucosa and thereby transmitted via venous and lymphatic channels to the uterus or to the general blood circulation.
The deposited drug or drug composition may include any polymer capable of producing and facilitating a coherent deposition on the polymeric support material. Such polymers include but are not limited to polyesters, olefins, cellulose and cellulose derivatives, PVA and PVP.
The polymeric support may be any polymeric material capable of serving as a support for the deposited material, and includes non-woven as well as woven materials. Examples of such support material include polypropylene, polyethylene, cellulose and cellulose derivatives or any other polymer which can be processed as a fiber.
A preferred shape of the polymeric support is a rectangular strip, which preferably consists of one or more layers, for example, 2-16 layers. Other shapes for the strip are also contemplated as part of the invention.
Examples of wetting agents which may be used in the drug delivery system of the invention include glycerol, polyethylene glycol (PEG), polypropylene glycol (PPG) and surfactants with an HLB ranging from 10 to 18 such as Tween 80.
Preferred wetting agents are glycerol and PEG-8000.
The delivery system of the invention is preferably used together with a catamenial tampon, as will be explained in more detail below.
(a) a deposition comprising an effective amount of the drug and, optionally, a wetting agent; and (b) a polymeric support on which the deposition is deposited.
In the present specification, the term "transvaginal" includes both local delivery to the vagina (intravaginal) as well as through the vagina to other target tissues in the body, including systemic effects.
The drug used in the delivery system of the invention may be any drug 1o which either is released and acts locally or which is absorbed through the vaginal mucosa to other locations in the body. Examples of such drugs include non-steroidal anti-inflammatory drugs (NSAID), anti-prostaglandins, prostaglandin inhibitors, COX-2 inhibitors, local anaesthetics, calcium channel blockers, potassium channel blockers, (3-adrenergic agonists, leukotriene blocking drugs, smooth muscle inhibitors, vasodilators, hormone replacement drugs, androgenic hormones and drugs capable of inhibiting dyskinetic muscle contraction.
Non-limiting examples of NSAIDs suitable for use in the method of the invention include Aspirin, Ibuprofen, Indoinethacin, Phenylbutazone, Bromfenac, Fenamate, Sulindac, Nabumetone, Ketorolac, and Naproxen. Examples of local anesthetics include Lidocaine, Mepivacaine, Etidocaine, Bupivacaine, 2-Chloroprocaine hydrochloride, Procaine, and Tetracaine hydrochloride.
Examples of calcium channel antagonists include Diltiazem, Israpidien, Nimodipine, Felodipine, Verapamil, Nifedipine, Nicardipine, and Bepridil. Examples of potassium channel blockers include Defetilide, E-403 1, Almokalant, Sematilide, Ambasilide, Azimilide, Tedisamil, RP58866, sotalol, Piroxicam, and Ibutilide.
Examples of p-adrenergic agonists include Terbutaline, Salbutamol, Metaproterenol, and Ritodrine. Vasodilators, which are believed to relieve muscle spasm in the uterine muscle, include nitroglycerin, isosorbide dinitrate and isosorbide mononitrate. Examples of COX-2 inhibitors are Celecoxib, Meloxicam and Flosulide. Examples of hormone replacement drugs are estrogen or estradiol and progestogen. Examples of androgenic hormones are testosterone and other androgenic hormones.
The drug may be present in the system in combination with a biocompatible excipient or carrier acceptable for application of the drug to the vaginal epithelium.
Although the mechanism may be diffusion-controlled, the co-inclusion of excipients such as wetting agents or surfactants in the formulation, may be necessary. The term "an effective amount" in this specification means an amount sufficient to attain a therapeutically effective amount of the drug in the target tissue or system. In a preferred embodiment, the drug is absorbable through the vaginal mucosa and thereby transmitted via venous and lymphatic channels to the uterus or to the general blood circulation.
The deposited drug or drug composition may include any polymer capable of producing and facilitating a coherent deposition on the polymeric support material. Such polymers include but are not limited to polyesters, olefins, cellulose and cellulose derivatives, PVA and PVP.
The polymeric support may be any polymeric material capable of serving as a support for the deposited material, and includes non-woven as well as woven materials. Examples of such support material include polypropylene, polyethylene, cellulose and cellulose derivatives or any other polymer which can be processed as a fiber.
A preferred shape of the polymeric support is a rectangular strip, which preferably consists of one or more layers, for example, 2-16 layers. Other shapes for the strip are also contemplated as part of the invention.
Examples of wetting agents which may be used in the drug delivery system of the invention include glycerol, polyethylene glycol (PEG), polypropylene glycol (PPG) and surfactants with an HLB ranging from 10 to 18 such as Tween 80.
Preferred wetting agents are glycerol and PEG-8000.
The delivery system of the invention is preferably used together with a catamenial tampon, as will be explained in more detail below.
Preferably, more than one delivery system will be placed in a tampon on different sides, so as to release the drug in all directions.
Among the advantages of using the delivery system of the invention for releasing a drug to the surrounding environment of the female urogenital tract is the contribution both to the economy of the manufacturing process of the tampon as well as to its reproducibility. In addition, the amount of drug necessary to use in the system to obtain a given effect may be significantly less than in systemic methods of drug administration.
In a second aspect of the invention, there is provided catamenial tampon 1o for insertion in a human vagina comprising:
(a) an inner core comprising an absorbent material;
(b) an outer layer comprising a liquid-permeable material; and (c) a delivery system according to the invention.
One or more of the polymeric supports or strips of the delivery system may be attached to the tampon, as will be described in detail below. Preferably, the delivery system is positioned between the inner core and the outer layer.
Optionally, the tampon further comprises a polymeric water-impermeable film behind the strips of the delivery system, e.g. between the delivery system and the inner core.
Preferably, the film is comprised of high-density polyethylene (HDPE).
In a third aspect of the invention, there is provided a method of transvaginal drug delivery comprising inserting a catamenial tampon into a vagina, wherein the catamenial tampon comprises:
(a) an inner core comprising an absorbent material;
(b) an outer layer comprising a liquid-permeable material; and (c) a transvaginal drug delivery system according to the invention.
Preferably, the drug is a NSAID such as naproxen or ibuprofen.
Among the advantages of using the delivery system of the invention for releasing a drug to the surrounding environment of the female urogenital tract is the contribution both to the economy of the manufacturing process of the tampon as well as to its reproducibility. In addition, the amount of drug necessary to use in the system to obtain a given effect may be significantly less than in systemic methods of drug administration.
In a second aspect of the invention, there is provided catamenial tampon 1o for insertion in a human vagina comprising:
(a) an inner core comprising an absorbent material;
(b) an outer layer comprising a liquid-permeable material; and (c) a delivery system according to the invention.
One or more of the polymeric supports or strips of the delivery system may be attached to the tampon, as will be described in detail below. Preferably, the delivery system is positioned between the inner core and the outer layer.
Optionally, the tampon further comprises a polymeric water-impermeable film behind the strips of the delivery system, e.g. between the delivery system and the inner core.
Preferably, the film is comprised of high-density polyethylene (HDPE).
In a third aspect of the invention, there is provided a method of transvaginal drug delivery comprising inserting a catamenial tampon into a vagina, wherein the catamenial tampon comprises:
(a) an inner core comprising an absorbent material;
(b) an outer layer comprising a liquid-permeable material; and (c) a transvaginal drug delivery system according to the invention.
Preferably, the drug is a NSAID such as naproxen or ibuprofen.
BRIEF DESCRIPTION OF THE DRAWINGS
In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:
Figs. la and 2a are perspective top views of a folded-type tampon in its flat form with two different embodiments of a delivery system in accordance with the invention;
Figs. lb and 2b are perspective views of a folded-type tampon in its final folded and pressed form;
Figs. lc and 2c are sectional views along lines lc-lc and 2c-2c in Figs.
lb and 2b, respectively;
Figs. 3a and 4a are perspective top views of a rolled-type tampon in its flat form with two different embodiments of a delivery system in accordance with the invention;
Figs. 3b and 4b are perspective views of a rolled-type tampon in its final, rolled and pressed form; and Figs. 3c and 4c are sectional views along lines 3c-3c and 4c-4c in Figs.
3b and 4b, respectively.
Fig. 5 shows release profiles of formulated tampons containing either 50 mg or 25 mg ibuprofen, in net enclosure permitting different fluid volume absorption (highest release value (%), after 4 hours of incubation, is annotated).. -50mg. very loose net, 10ml; ^ - 50mg. loose net, 8.9m1; ^ - 50mg. tight net, 6ml; = -25mg tight net, 6m1;
Figs. 6a and 6b show embodiments of alternate structures of the delivery system with a polymeric film backing: a split arrangement (Fig. 6a) and a continuous arrangement (Fig. 6b);
Fig. 7 shows release profiles of tampons, enclosed in a tight net, containing 100mg of Ibuprofen and 25% glycerol with the delivery system attached to HDPE
substrate type A (results of two replicas);
In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:
Figs. la and 2a are perspective top views of a folded-type tampon in its flat form with two different embodiments of a delivery system in accordance with the invention;
Figs. lb and 2b are perspective views of a folded-type tampon in its final folded and pressed form;
Figs. lc and 2c are sectional views along lines lc-lc and 2c-2c in Figs.
lb and 2b, respectively;
Figs. 3a and 4a are perspective top views of a rolled-type tampon in its flat form with two different embodiments of a delivery system in accordance with the invention;
Figs. 3b and 4b are perspective views of a rolled-type tampon in its final, rolled and pressed form; and Figs. 3c and 4c are sectional views along lines 3c-3c and 4c-4c in Figs.
3b and 4b, respectively.
Fig. 5 shows release profiles of formulated tampons containing either 50 mg or 25 mg ibuprofen, in net enclosure permitting different fluid volume absorption (highest release value (%), after 4 hours of incubation, is annotated).. -50mg. very loose net, 10ml; ^ - 50mg. loose net, 8.9m1; ^ - 50mg. tight net, 6ml; = -25mg tight net, 6m1;
Figs. 6a and 6b show embodiments of alternate structures of the delivery system with a polymeric film backing: a split arrangement (Fig. 6a) and a continuous arrangement (Fig. 6b);
Fig. 7 shows release profiles of tampons, enclosed in a tight net, containing 100mg of Ibuprofen and 25% glycerol with the delivery system attached to HDPE
substrate type A (results of two replicas);
Fig. 8 shows release profiles of tampons, enclosed in a tight net, containing 100mg of Ibuprofen and 10% Tween-80 with the delivery system attached to HDPE substrate type A (+) and type B (.); and Fig. 9 shows release profiles of tampons, enclosed in a tight net, containing 150mg of Ibuprofen, 20% glycerol and 20% PEG-900 (without HDPE substrates) (results of two replicas a (0) and b (=)).
DETAILED DESCRIPTION OF SPECIFIC EMBODIMENTS
1. Delivery System The delivery system of the invention is composed of a polymeric support, io such as a non-woven polymer material, on which a deposition is deposited.
The deposition comprises a drug which may be released to the surrounding environment. Examples of such drugs are listed above in the summary of the invention. In one embodiment, the drug is dissolved in a solvent which is applied to the support. The deposition is deposited by evaporation of the solvent The polymeric support is placed near the surface of the tampon. Preferably, the delivery system is positioned between the inner absorbent core of the tampon and its outer covering layer. The polymeric support may be in any geometrical form or shape. Preferably, the support is in the form of rectangular strips of material, although other shapes are also possible. A plurality of these strips may be placed on different sides of the tampon in order to release the drug in all directions.
In the following discussion, several non-limiting examples are provided of tampons prepared according to the invention.
Example 1 Tampons which undergo both radial and longitudinal expansion are generally manufactured for use with various types of applicator devices. The longitudinal expansion is generally more than 10% of its unexpanded length.
This type of tampon comprises an inner core of absorbent material, such as cellulose fibers and/or cotton fibers, enveloped by an outer layer of liquid-permeable material such as a non-woven polymer, as for example polypropylene, polyethylene, polyester, cellulose, cellulose derivatives, or any combination of the above. This type of tampon is referred to in this specification as a `folded-type"
tampon.
A folded-type tampon according to one embodiment of the invention is illustrated in Fig. la, in which can be seen a tampon 2 in its flat form comprising a body 4 and a withdrawal cord 6. The body 4 of the tampon comprises an outer layer 8 enveloping an inner absorbent core 10. The outer layer is held to the inner core in ways well known in the art, such as sewing or welding. The flat body has an upper 12 and a lower 14 surface.
In this embodiment, a delivery system according to the invention in the form of three rectangular polymeric strips are positioned between the outer layer and the inner core, in parallel to the longitudinal axis of the body. One relatively wide strip 16 is on the upper surface 12 of the body (under the outer layer 8) and two narrow strips 18 are on the lower surface 14. The length of the strips may be approximately equal to the length of the flat body, and preferably equal to it.
Preferably, the width of the wide strip is approximately twice the width of the narrow strips. Typical, non-limiting dimensions may be as follows: length and width of flat tampon - 5-9.5 and 4-5 cm, respectively; widths of wide and narrow strips - 1.5-2.5 cm and 0.7-1.5 cm, respectively.
When the tampon is folded, it is compressed both lengthwise and widthwise to form the conventional tampon shape, as shown in Fig. lb. The strips 18 are aligned near the outer surface of the body of the tampon. The tampon takes on a W-like shape in cross-section, as illustrated in Fig. lc, in which can be seen the inner core 10, the outer layer 8 and the wide 16 and narrow 18 strips below the outer layer. It may be seen from the figure that the edges of the wide strip 16 are folded within the folds of the inner core 10, thereby releasing the drug absorbed therein to within the tampon as well as to the surrounding environment.
DETAILED DESCRIPTION OF SPECIFIC EMBODIMENTS
1. Delivery System The delivery system of the invention is composed of a polymeric support, io such as a non-woven polymer material, on which a deposition is deposited.
The deposition comprises a drug which may be released to the surrounding environment. Examples of such drugs are listed above in the summary of the invention. In one embodiment, the drug is dissolved in a solvent which is applied to the support. The deposition is deposited by evaporation of the solvent The polymeric support is placed near the surface of the tampon. Preferably, the delivery system is positioned between the inner absorbent core of the tampon and its outer covering layer. The polymeric support may be in any geometrical form or shape. Preferably, the support is in the form of rectangular strips of material, although other shapes are also possible. A plurality of these strips may be placed on different sides of the tampon in order to release the drug in all directions.
In the following discussion, several non-limiting examples are provided of tampons prepared according to the invention.
Example 1 Tampons which undergo both radial and longitudinal expansion are generally manufactured for use with various types of applicator devices. The longitudinal expansion is generally more than 10% of its unexpanded length.
This type of tampon comprises an inner core of absorbent material, such as cellulose fibers and/or cotton fibers, enveloped by an outer layer of liquid-permeable material such as a non-woven polymer, as for example polypropylene, polyethylene, polyester, cellulose, cellulose derivatives, or any combination of the above. This type of tampon is referred to in this specification as a `folded-type"
tampon.
A folded-type tampon according to one embodiment of the invention is illustrated in Fig. la, in which can be seen a tampon 2 in its flat form comprising a body 4 and a withdrawal cord 6. The body 4 of the tampon comprises an outer layer 8 enveloping an inner absorbent core 10. The outer layer is held to the inner core in ways well known in the art, such as sewing or welding. The flat body has an upper 12 and a lower 14 surface.
In this embodiment, a delivery system according to the invention in the form of three rectangular polymeric strips are positioned between the outer layer and the inner core, in parallel to the longitudinal axis of the body. One relatively wide strip 16 is on the upper surface 12 of the body (under the outer layer 8) and two narrow strips 18 are on the lower surface 14. The length of the strips may be approximately equal to the length of the flat body, and preferably equal to it.
Preferably, the width of the wide strip is approximately twice the width of the narrow strips. Typical, non-limiting dimensions may be as follows: length and width of flat tampon - 5-9.5 and 4-5 cm, respectively; widths of wide and narrow strips - 1.5-2.5 cm and 0.7-1.5 cm, respectively.
When the tampon is folded, it is compressed both lengthwise and widthwise to form the conventional tampon shape, as shown in Fig. lb. The strips 18 are aligned near the outer surface of the body of the tampon. The tampon takes on a W-like shape in cross-section, as illustrated in Fig. lc, in which can be seen the inner core 10, the outer layer 8 and the wide 16 and narrow 18 strips below the outer layer. It may be seen from the figure that the edges of the wide strip 16 are folded within the folds of the inner core 10, thereby releasing the drug absorbed therein to within the tampon as well as to the surrounding environment.
Example 2 In another embodiment, illustrated in Fig. 2a, three strips are positioned at spaced intervals between the outer layer 22 and the inner core 24 of the flat tampon 28, perpendicularly to the longitudinal axis of the flat body 26 of the tampon. In this embodiment, the strips are wound around the width of the body 26 and then excised at the lateral edges 30 of the body so that there are 3 strips 20 on the upper surface 32 of the body and 3 corresponding strips 34 on the underside of the body.
The length of each of the strips is equal to the width of the flat tampon.
Preferably, the strips are positioned closer to the front end 36 of the tampon, opposite the lo withdrawal cord 3 8, since this is the end with which the menstrual fluid first comes into contact.
The folded tampon 40 is illustrated in Fig. 2b, in which can be seen the annular strips 20. Fig. 2c shows how the strips 20,34 appear near the outer surface of the tampon between the outer layer 22 and the inner core 24, as well as within the folds of the inner core.
Example 3 A typical tampon which undergoes primarily radial expansion (<10%
longitudinal expansion, if at all) is referred to in this specification as a "rolled-type"
tampon and is shown in Figs. 3a-3c. As in the folded-type tampon described above, it comprises an inner core of absorbent material, as in Example 1, enveloped by an outer layer of liquid-permeable material, as in Example 1. The rolled-type tampon differs from the folded-type tampon, inter alia, in their dimensions as well as in the manner of forming of the tampon. These differences affect the placement of the strips.
As shown in Fig. 3a, the flat tampon 48 comprises an absorbent layer 50 on which is placed an outer layer 52. The absorbent layer 50 is in the form of an extended rectangular ribbon. The material of the outer layer 52 is generally heat sealed to the upper side of the absorbent layer near one of its ends 54, an extension 56 of the outer layer partly extending beyond the end 54 of the absorbent layer. The - 12 - PCT/lB02/00528 length of the extension 56 is substantially equivalent to the circumference of the tampon in its final, folded form.
According to one embodiment of the invention, three parallel spaced rectangular polymeric strips 58 are positioned equidistantly from each other, perpendicular to the longitudinal axis of the outer layer, and between the absorbent layer 50 and the outer layer 52. The ends of the strips are distanced from the longitudinal edges of the outer layer, and the strip 60 closest the end 54 of the absorbent layer is inwardly displaced from that end. The distance from the strip 62 farthest from the end 54 of the absorbent layer to that end is approximately equal to the circumference of the tampon in its folded form.
Typical, non-limiting dimensions of the various tampon components are given below for exemplary purposes only: length, width and thickness of absorbent layer-20-30 cm, 4-6 cm and 0.4-1. 0 cm, respectively; length and width of outer layer-5-15 cm and 4-4.5 cm; circumference of tampon-3-4.5 cm; length of strips - 3. 5-5. 5 cm.
Fig. 3b shows the tampon 64 in its folded form comprising the body 66 and withdrawal cord 68. During the forming process, the absorbent layer of the flat tampon (Fig.
3a) is rolled up onto itself along its longitudinal axis towards the end on which the strips and outer layer are placed, and the extension 56 of the outer layer is heat welded to the opposite end of the outer layer, thus enveloping the absorbent layer which now forms the core of the tampon. Two of the three strips 58 may be seen in Fig. 3b through the outer layer, with the third strip out of sight behind the body of the tampon. Fig.
3c shows the three components of the tampon according to the invention: the rolled up inner absorbent core 50, the outer layer 52 and the strips 58.
Example 4 In this embodiment, illustrated in Figs. 4a-4c, the strips are placed parallel to the longitudinal axis of the outer layer rather than perpendicular thereto. Thus, Fig. 4a illustrates the absorbent layer 50 and outer layer 52 of the flat tampon 63 as in the previous example. Three parallel equidistant strips 65 are placed between the DOCSOTT: 614523\2 two layers in parallel to the longitudinal axis of the outer layer. The length of each strip is equal to the circumference of the tampon in its final form. Preferably, the strips are placed proximate to the anterior end of the folded tampon.
Figs. 4b and 4c show the tampon 67 in its folded form comprising the inner core 50, the outer layer 52 and the strips 65.
II. In Vitro Experiments A. Introduction The following is a summary of the main results and conclusions of in vitro release studies, conducted with two selected NSAIDs, Naproxen and Ibuprofen, using the delivery system of the invention.
Due to the relatively hydrophobic nature of Naproxen and Ibuprofen, special attention should be given to the potential extent of bioavailability of the drugs, from the formulated tampons as a result of the small fluid volume in the vagina during menstruation (5-8 ml). The availability of the drugs is mainly governed by two processes:
Vaginal mucosa tissue penetration, which in this case is not considered a limiting factor, and the release pattern of the drugs from the formulated tampons, the dependence of which is mainly affected by drug aqueous solubility and diffusion.
Normally, in the case of in vitro release studies of relatively hydrophobic drugs with good tissue penetration, the experiments are conducted under "SINK
conditions". The term SINK conditions originated from the fact that the drug concentration gradient between the external and internal epithelial layer is always maximal, and that the tissue or blood acts as a natural 'sink', i. e. the drug is instantaneously absorbed the moment it dissolves.
Therefore, under in vivo conditions, there is no concentration build up and hence the retarding effect of low and/or moderate concentration gradient in unlikely to occur. In order to simulate the in vivo sink conditions, in vitro dissolution or release kinetics studies are usually conducted using a large volume of dissolution or release medium, so that the solute concentration never reaches more than 5-10% of its maximum solubility under DOCSOTT: 614523\2 identical experimental conditions. If such conditions are maintained, the low aqueous solubility of the drug does not represent anymore a rate -limiting factor.
All in vitro tests in this specification were conducted under sink conditions using 10% of maximum solubility concentration, unless otherwise specified.
B. Materials and Methods Materials:
Both drugs were kindly provided by Teva Pharmaceuticals, Ltd., Israel, and are of pharmacopoeia grade. All other ingredients used in the study were analytical or HPLC grade.
Methods:
1. Preparation of delivery system:
Based on previous knowledge, the following formulation was retained: each one of the drugs was first dissolved in ethanol, at a concentration determined by the drug dosage per tampon, and glycerol was added to a percentage of 15%
calculated on drug weight basis. Glycerol acts as a wetting agent. The co-inclusion of other wetting agents or surfactants in the formulation may be necessary at times.
The formulation was loaded on non-woven (NW) strip (7.5-8.5x2.5 cm) (i.e. the delivery system), by immersing the NW in an ethanol solution, containing the formulation, and eventually evaporating the solvent. Both ethanol and acetone were found suitable for this method, nevertheless, ethanol was chosen due to its significantly lower toxicity.
The formulation-containing strips of the folded-type were folded 2 times around the axial direction and 7.5 cm-long strips were prepared by pressing the folded material at 1 ton/cm2 for 30 seconds. 4 layered strips were obtained by using a single PP/PE (NW). One 2.5cm strip and two 1.25cm strips were attached to a tampon in the longitudinal direction as shown in Fig. 1a.
The dose preliminarily chosen, was 50 mg of the drug per tampon and was compared with different lower and higher doses, in terms of release pattern efficiency. For simplicity and clarity reasons, the two drugs chosen for this study 3o are dealt with separately.
The length of each of the strips is equal to the width of the flat tampon.
Preferably, the strips are positioned closer to the front end 36 of the tampon, opposite the lo withdrawal cord 3 8, since this is the end with which the menstrual fluid first comes into contact.
The folded tampon 40 is illustrated in Fig. 2b, in which can be seen the annular strips 20. Fig. 2c shows how the strips 20,34 appear near the outer surface of the tampon between the outer layer 22 and the inner core 24, as well as within the folds of the inner core.
Example 3 A typical tampon which undergoes primarily radial expansion (<10%
longitudinal expansion, if at all) is referred to in this specification as a "rolled-type"
tampon and is shown in Figs. 3a-3c. As in the folded-type tampon described above, it comprises an inner core of absorbent material, as in Example 1, enveloped by an outer layer of liquid-permeable material, as in Example 1. The rolled-type tampon differs from the folded-type tampon, inter alia, in their dimensions as well as in the manner of forming of the tampon. These differences affect the placement of the strips.
As shown in Fig. 3a, the flat tampon 48 comprises an absorbent layer 50 on which is placed an outer layer 52. The absorbent layer 50 is in the form of an extended rectangular ribbon. The material of the outer layer 52 is generally heat sealed to the upper side of the absorbent layer near one of its ends 54, an extension 56 of the outer layer partly extending beyond the end 54 of the absorbent layer. The - 12 - PCT/lB02/00528 length of the extension 56 is substantially equivalent to the circumference of the tampon in its final, folded form.
According to one embodiment of the invention, three parallel spaced rectangular polymeric strips 58 are positioned equidistantly from each other, perpendicular to the longitudinal axis of the outer layer, and between the absorbent layer 50 and the outer layer 52. The ends of the strips are distanced from the longitudinal edges of the outer layer, and the strip 60 closest the end 54 of the absorbent layer is inwardly displaced from that end. The distance from the strip 62 farthest from the end 54 of the absorbent layer to that end is approximately equal to the circumference of the tampon in its folded form.
Typical, non-limiting dimensions of the various tampon components are given below for exemplary purposes only: length, width and thickness of absorbent layer-20-30 cm, 4-6 cm and 0.4-1. 0 cm, respectively; length and width of outer layer-5-15 cm and 4-4.5 cm; circumference of tampon-3-4.5 cm; length of strips - 3. 5-5. 5 cm.
Fig. 3b shows the tampon 64 in its folded form comprising the body 66 and withdrawal cord 68. During the forming process, the absorbent layer of the flat tampon (Fig.
3a) is rolled up onto itself along its longitudinal axis towards the end on which the strips and outer layer are placed, and the extension 56 of the outer layer is heat welded to the opposite end of the outer layer, thus enveloping the absorbent layer which now forms the core of the tampon. Two of the three strips 58 may be seen in Fig. 3b through the outer layer, with the third strip out of sight behind the body of the tampon. Fig.
3c shows the three components of the tampon according to the invention: the rolled up inner absorbent core 50, the outer layer 52 and the strips 58.
Example 4 In this embodiment, illustrated in Figs. 4a-4c, the strips are placed parallel to the longitudinal axis of the outer layer rather than perpendicular thereto. Thus, Fig. 4a illustrates the absorbent layer 50 and outer layer 52 of the flat tampon 63 as in the previous example. Three parallel equidistant strips 65 are placed between the DOCSOTT: 614523\2 two layers in parallel to the longitudinal axis of the outer layer. The length of each strip is equal to the circumference of the tampon in its final form. Preferably, the strips are placed proximate to the anterior end of the folded tampon.
Figs. 4b and 4c show the tampon 67 in its folded form comprising the inner core 50, the outer layer 52 and the strips 65.
II. In Vitro Experiments A. Introduction The following is a summary of the main results and conclusions of in vitro release studies, conducted with two selected NSAIDs, Naproxen and Ibuprofen, using the delivery system of the invention.
Due to the relatively hydrophobic nature of Naproxen and Ibuprofen, special attention should be given to the potential extent of bioavailability of the drugs, from the formulated tampons as a result of the small fluid volume in the vagina during menstruation (5-8 ml). The availability of the drugs is mainly governed by two processes:
Vaginal mucosa tissue penetration, which in this case is not considered a limiting factor, and the release pattern of the drugs from the formulated tampons, the dependence of which is mainly affected by drug aqueous solubility and diffusion.
Normally, in the case of in vitro release studies of relatively hydrophobic drugs with good tissue penetration, the experiments are conducted under "SINK
conditions". The term SINK conditions originated from the fact that the drug concentration gradient between the external and internal epithelial layer is always maximal, and that the tissue or blood acts as a natural 'sink', i. e. the drug is instantaneously absorbed the moment it dissolves.
Therefore, under in vivo conditions, there is no concentration build up and hence the retarding effect of low and/or moderate concentration gradient in unlikely to occur. In order to simulate the in vivo sink conditions, in vitro dissolution or release kinetics studies are usually conducted using a large volume of dissolution or release medium, so that the solute concentration never reaches more than 5-10% of its maximum solubility under DOCSOTT: 614523\2 identical experimental conditions. If such conditions are maintained, the low aqueous solubility of the drug does not represent anymore a rate -limiting factor.
All in vitro tests in this specification were conducted under sink conditions using 10% of maximum solubility concentration, unless otherwise specified.
B. Materials and Methods Materials:
Both drugs were kindly provided by Teva Pharmaceuticals, Ltd., Israel, and are of pharmacopoeia grade. All other ingredients used in the study were analytical or HPLC grade.
Methods:
1. Preparation of delivery system:
Based on previous knowledge, the following formulation was retained: each one of the drugs was first dissolved in ethanol, at a concentration determined by the drug dosage per tampon, and glycerol was added to a percentage of 15%
calculated on drug weight basis. Glycerol acts as a wetting agent. The co-inclusion of other wetting agents or surfactants in the formulation may be necessary at times.
The formulation was loaded on non-woven (NW) strip (7.5-8.5x2.5 cm) (i.e. the delivery system), by immersing the NW in an ethanol solution, containing the formulation, and eventually evaporating the solvent. Both ethanol and acetone were found suitable for this method, nevertheless, ethanol was chosen due to its significantly lower toxicity.
The formulation-containing strips of the folded-type were folded 2 times around the axial direction and 7.5 cm-long strips were prepared by pressing the folded material at 1 ton/cm2 for 30 seconds. 4 layered strips were obtained by using a single PP/PE (NW). One 2.5cm strip and two 1.25cm strips were attached to a tampon in the longitudinal direction as shown in Fig. 1a.
The dose preliminarily chosen, was 50 mg of the drug per tampon and was compared with different lower and higher doses, in terms of release pattern efficiency. For simplicity and clarity reasons, the two drugs chosen for this study 3o are dealt with separately.
2. Release of Ibuprofen: In vitro release kinetics conditions:
SINK conditions:
The release medium used for these experiments was the Sorensen -Walbum buffer, chosen here due to its lack of absorbance in the UV range, thus causing less interference with the analytical drug detection process. The buffer consisted of glycine (0.1 M) and NaCl (0.1 M), adjusted to pH 7.4 with NaOH (0. 1M).
In order to establish SINK conditions, the saturation concentration of Ibuprofen, under the release conditions, was determined. A large excess of Ibuprofen was added to 50 ml of the Sorensen buffer and agitated in a sealed flask 1o at 37 C, for a period of 24 hours The saturation concentration of Ibuprofen under these conditions, as determined by HPLC, was 100 g/ml. Accordingly, the SINK conditions concentration was set to 10 g/ml. It is worth mentioning that a significantly higher saturation concentration can be reached by first dissolving the drug in a small quantity of ethanol and then mixing it with the buffer solution. Nevertheless, these are not the conditions under which the drug is released in vitro or in vivo.
3. HPLC method for Ibuprofen determination:
Ibuprofen concentrations were determined by means of high performance liquid chromatography (HPLC), using the method described in Pharmaceutical Research (1998) 15:482-487.
Column: RP-C18, 5 m, 25 cm, (Merck) at ambient temperature.
Flow rate: 2ml/min.
Isocratic mobile phase: acetonitrile: O.1M sodium acetate (35:65 v/v), adjusted to pH 6.2 with glacial acetic acid.
UV detector at 222 mn.
Detection limit: 0.05 g/ml.
The linear relation of peak area to calibration concentrations obtained in a concentration range of 0 - 2000 g/ml was linear and yielded an r value higher than 0.99.
SINK conditions:
The release medium used for these experiments was the Sorensen -Walbum buffer, chosen here due to its lack of absorbance in the UV range, thus causing less interference with the analytical drug detection process. The buffer consisted of glycine (0.1 M) and NaCl (0.1 M), adjusted to pH 7.4 with NaOH (0. 1M).
In order to establish SINK conditions, the saturation concentration of Ibuprofen, under the release conditions, was determined. A large excess of Ibuprofen was added to 50 ml of the Sorensen buffer and agitated in a sealed flask 1o at 37 C, for a period of 24 hours The saturation concentration of Ibuprofen under these conditions, as determined by HPLC, was 100 g/ml. Accordingly, the SINK conditions concentration was set to 10 g/ml. It is worth mentioning that a significantly higher saturation concentration can be reached by first dissolving the drug in a small quantity of ethanol and then mixing it with the buffer solution. Nevertheless, these are not the conditions under which the drug is released in vitro or in vivo.
3. HPLC method for Ibuprofen determination:
Ibuprofen concentrations were determined by means of high performance liquid chromatography (HPLC), using the method described in Pharmaceutical Research (1998) 15:482-487.
Column: RP-C18, 5 m, 25 cm, (Merck) at ambient temperature.
Flow rate: 2ml/min.
Isocratic mobile phase: acetonitrile: O.1M sodium acetate (35:65 v/v), adjusted to pH 6.2 with glacial acetic acid.
UV detector at 222 mn.
Detection limit: 0.05 g/ml.
The linear relation of peak area to calibration concentrations obtained in a concentration range of 0 - 2000 g/ml was linear and yielded an r value higher than 0.99.
4. Release of Naproxen: In vitro release kinetics conditions SINK conditions:
In order to establish sink conditions, the saturation concentration of Naproxen, under the release kinetics experimental conditions, was determined, in the same manner as described before for Ibuprofen. A large excess of Naproxen was added to 50 ml of the Sorensen buffer and agitated in a sealed flask at 37 C, for a period of 24 hours.
The saturation concentration of Naproxen under these conditions, as determined by HPLC, was 109 ghnl, only slightly higher than that of Ibuprofen.
to Accordingly, the sink conditions concentration was set to 10.9 g/ml, which is 10%
of the saturation conditions.
5. HPLC method:
Naproxen concentrations were determined by HPLC using the method described in Acta Pharmacol. et Toxicol. (1980) 47:267-273.
Column: RP-C18, 5p in 25mm, (Merck) at ambient temperature.
Flow rate: 2ml/min.
Isocratic mobile phase: acetonitrile : 100mM ammonium acetate (40:60 v/v), adjusted to pH 5.5 with glacial acetic acid.
W detector at 280 rim.
Detection limit: 0.02 g/ml.
The linear relation of peak area to calibration concentrations obtained in a concentration range of 0 - 2000 gg/ml was linear and yielded an r value higher than 0.99.
Results 1. Fluid absorption Formulated tampons (with either ibuprofen or naproxen) were enclosed in a flexible plastic net. The net was firmly tied around the tampons, so that it allowed a maximum absorption of 6 ml of the release medium, which is close to the absorption volume of menstrual fluids under physiological conditions. For comparison purposes, the extent of net tightness was decreased to allow a final absorption volume of 8-10 ml.
Fig. 5 summarizes the ibuprofen release results obtained comparing the effect of two parameters - fluid absorption and amount of formulation - on the drug release profile.
Although some effect of the formulation amount is observed, the most significant factor influencing the release profile is the fluid absorption volume.
Increasing the absorption volume from 6 ml to 8.9 ml and finally to 10 ml, led to an increase in drug release from 32% to 61% and to 97%, respectively.
At this stage, it was concluded that the drug release rate from a tampon will markedly depend on the fluid absorption. It is worth mentioning though, that in vitro the fluid absorption was mainly governed by the expansion ability of the tampon, which was restricted by the net enclosure. Under in vivo conditions, however, the tampon is in a significantly more expanded form with the same fluid Is absorption volume.
2. Release studies of naproxen from tampons containing a delivery system attached to HDPE substrates:
In an attempt to enhance the drug release kinetics, the formulated delivery system was attached to a thin film of high-density polyethylene (HDPE) which is a relatively inert and hydrophobic material, impermeable to water. The main concept of placing a thin HDPE substrate attached to the formulated chip was to facilitate the outward diffusion of the drug by minimizing the inward flow. The HDPE
substrate was attached to the delivery system by sewing the edges with a cotton thread. The chip was mounted on the tampon with the HDPE substrate facing inward.
Two different approaches were tested. In one approach (type-A - Fig. 6a), a split HDPE substrate 70 was used, being only slightly larger than each of the formulated NW strips 72. In the second approach (type-B - Fig. 6b), a continuous substrate 74 was used covering almost the total area on each side of the tampon behind the formulated NW strips 76. A loose net enclosure was used, allowing a maximum fluid absorption of 10 ml.
3. Release studies of ibuprofen from tampons in an albumin-containing release medium Among the various parameters tested, it is the drug solubility and possibly its diffusion pattern that constitute the principle limiting factors in the drug release process. Thus, it was considered that the use of the Sorensen buffer alone as a release medium might not closely enough resemble the physico-chemical properties of the menstrual fluid, in terms of drug dissolution.
Consequently, a plasma protein - albumin - was dissolved in the Sorensen buffer at a concentration of either 1% or 3%, the latter being the actual albumin concentration in the blood.
4. Measurement of saturation concentration - Determination of SINK
conditions:
An excess amount of drug -(Ibuprofen) was added to 30 ml of Sorensen buffer (pH 7.4), containing either 1% or 3% of dissolved albumin, and agitated in sealed flasks at 37 C, for a period of 24h. The solution concentration was determined by HPLC.
The saturation concentrations obtained with the 1% and 3% albumin containing buffer solutions were approximately 730 pg/ml and 2100 pg/ml, respectively. These concentrations are respectively 7 to 21 times higher than the 100 pg/ml saturation concentration obtained with the Sorensen buffer alone. It is believed that either a complexation process between the protein and drug molecules, or a change in the solubility parameters of the solution led to such a significant increase in the drug saturation concentration.
SINK conditions were set at 6.8% and 14% for formulated tampons containing 50 mg and 100 mg of ibuprofen, respectively, in a volume of 1 liter of releasing medium containing 1% bovine serum albumin.
In order to establish sink conditions, the saturation concentration of Naproxen, under the release kinetics experimental conditions, was determined, in the same manner as described before for Ibuprofen. A large excess of Naproxen was added to 50 ml of the Sorensen buffer and agitated in a sealed flask at 37 C, for a period of 24 hours.
The saturation concentration of Naproxen under these conditions, as determined by HPLC, was 109 ghnl, only slightly higher than that of Ibuprofen.
to Accordingly, the sink conditions concentration was set to 10.9 g/ml, which is 10%
of the saturation conditions.
5. HPLC method:
Naproxen concentrations were determined by HPLC using the method described in Acta Pharmacol. et Toxicol. (1980) 47:267-273.
Column: RP-C18, 5p in 25mm, (Merck) at ambient temperature.
Flow rate: 2ml/min.
Isocratic mobile phase: acetonitrile : 100mM ammonium acetate (40:60 v/v), adjusted to pH 5.5 with glacial acetic acid.
W detector at 280 rim.
Detection limit: 0.02 g/ml.
The linear relation of peak area to calibration concentrations obtained in a concentration range of 0 - 2000 gg/ml was linear and yielded an r value higher than 0.99.
Results 1. Fluid absorption Formulated tampons (with either ibuprofen or naproxen) were enclosed in a flexible plastic net. The net was firmly tied around the tampons, so that it allowed a maximum absorption of 6 ml of the release medium, which is close to the absorption volume of menstrual fluids under physiological conditions. For comparison purposes, the extent of net tightness was decreased to allow a final absorption volume of 8-10 ml.
Fig. 5 summarizes the ibuprofen release results obtained comparing the effect of two parameters - fluid absorption and amount of formulation - on the drug release profile.
Although some effect of the formulation amount is observed, the most significant factor influencing the release profile is the fluid absorption volume.
Increasing the absorption volume from 6 ml to 8.9 ml and finally to 10 ml, led to an increase in drug release from 32% to 61% and to 97%, respectively.
At this stage, it was concluded that the drug release rate from a tampon will markedly depend on the fluid absorption. It is worth mentioning though, that in vitro the fluid absorption was mainly governed by the expansion ability of the tampon, which was restricted by the net enclosure. Under in vivo conditions, however, the tampon is in a significantly more expanded form with the same fluid Is absorption volume.
2. Release studies of naproxen from tampons containing a delivery system attached to HDPE substrates:
In an attempt to enhance the drug release kinetics, the formulated delivery system was attached to a thin film of high-density polyethylene (HDPE) which is a relatively inert and hydrophobic material, impermeable to water. The main concept of placing a thin HDPE substrate attached to the formulated chip was to facilitate the outward diffusion of the drug by minimizing the inward flow. The HDPE
substrate was attached to the delivery system by sewing the edges with a cotton thread. The chip was mounted on the tampon with the HDPE substrate facing inward.
Two different approaches were tested. In one approach (type-A - Fig. 6a), a split HDPE substrate 70 was used, being only slightly larger than each of the formulated NW strips 72. In the second approach (type-B - Fig. 6b), a continuous substrate 74 was used covering almost the total area on each side of the tampon behind the formulated NW strips 76. A loose net enclosure was used, allowing a maximum fluid absorption of 10 ml.
3. Release studies of ibuprofen from tampons in an albumin-containing release medium Among the various parameters tested, it is the drug solubility and possibly its diffusion pattern that constitute the principle limiting factors in the drug release process. Thus, it was considered that the use of the Sorensen buffer alone as a release medium might not closely enough resemble the physico-chemical properties of the menstrual fluid, in terms of drug dissolution.
Consequently, a plasma protein - albumin - was dissolved in the Sorensen buffer at a concentration of either 1% or 3%, the latter being the actual albumin concentration in the blood.
4. Measurement of saturation concentration - Determination of SINK
conditions:
An excess amount of drug -(Ibuprofen) was added to 30 ml of Sorensen buffer (pH 7.4), containing either 1% or 3% of dissolved albumin, and agitated in sealed flasks at 37 C, for a period of 24h. The solution concentration was determined by HPLC.
The saturation concentrations obtained with the 1% and 3% albumin containing buffer solutions were approximately 730 pg/ml and 2100 pg/ml, respectively. These concentrations are respectively 7 to 21 times higher than the 100 pg/ml saturation concentration obtained with the Sorensen buffer alone. It is believed that either a complexation process between the protein and drug molecules, or a change in the solubility parameters of the solution led to such a significant increase in the drug saturation concentration.
SINK conditions were set at 6.8% and 14% for formulated tampons containing 50 mg and 100 mg of ibuprofen, respectively, in a volume of 1 liter of releasing medium containing 1% bovine serum albumin.
5. In vitro drug release procedure:
The in vitro experimental conditions were set as follows: Drug release from formulated tampons was performed in a dissolution apparatus, consisting of 6 1-liter glass vessels immersed in a controlled temperature water bath and equipped with a controlled mechanical stirring system (130 rpm). Albumin concentration in the releasing medium was 1% and the solution was kept at a constant temperature of 37 C.
Formulated tampons were enclosed in a tight plastic net, restricting the maximum fluid absorption to 5-6 ml. The tampons were immersed into the io releasing medium head down, held vertically by the string. A small glass weight was attached to the tampon, in order to prevent floating. All experiments were carried out in two replicas. Samples were taken in duplicates and treated as described in the previous section.
Following the release process, the tampons were washed with 50 ml of ethanol in order to extract the residual amounts of drug present in the tampon at the end of the process. The sum of the residual and the released amounts was considered as the total amount of drug originally present in the formulated tampon.
The percent of drug release was thus calculated.
6. Release studies results:
Among the different formulations previously tested three versions were selected and compared under the new experimental conditions. These formulations differed in several parameters, i.e. the amount of drug per tampon, the type and amount of wetting agent, and the presence or absence of an HDPE substrate attached to the inner side of the formulated delivery system mounted on the tampons.
The selected formulations were as follows:
(a) 100 mg Ibuprofen* + 25% glycerol; split HDPE substrate (b) 100 mg Ibuprofen* + 10% Tween 80; split HDPE substrate (c) 100 mg Ibuprofen* + 10% Tween 80; continuous HDPE substrate (d) 150 mg Ibuprofen* + 20% glycerol + 20% PEG 1000; no HDPE
* amounts per tampon The release profiles of the different forinulated tampons, are presented in Figs. 7, 8 and 9.
The release profile of formulation number (a), under tight net enclosure conditions, is depicted in Fig. 7. It can clearly be observed, that most of the formulation is released within the first 2 hours. The release profiles of formulation numbers (b) and (c), shown in Fig. 8 clearly indicate that the use of Tween 80 as wetting agent instead of glycerol, does not increase the release rate and even slows it down. No significant difference in the release profiles was observed when using either split or continuous HDPE substrates.
Finally, it can be noted from Fig. 9 that the release profile of the drug from a tampon including glycerol and PEG- 1000 as wetting agents and no HDPE
substrate (formulation (d)) was markedly reduced. Only 50-60% of the drug was released within 120 minutes, as compared to the approximately 80% of the drug which were released within the same period of time when using an HDPE substrate (Fig. 7).
It is therefore suggested that the use of an HDPE substrate does promote and increase the rate of drug release.
The in vitro experimental conditions were set as follows: Drug release from formulated tampons was performed in a dissolution apparatus, consisting of 6 1-liter glass vessels immersed in a controlled temperature water bath and equipped with a controlled mechanical stirring system (130 rpm). Albumin concentration in the releasing medium was 1% and the solution was kept at a constant temperature of 37 C.
Formulated tampons were enclosed in a tight plastic net, restricting the maximum fluid absorption to 5-6 ml. The tampons were immersed into the io releasing medium head down, held vertically by the string. A small glass weight was attached to the tampon, in order to prevent floating. All experiments were carried out in two replicas. Samples were taken in duplicates and treated as described in the previous section.
Following the release process, the tampons were washed with 50 ml of ethanol in order to extract the residual amounts of drug present in the tampon at the end of the process. The sum of the residual and the released amounts was considered as the total amount of drug originally present in the formulated tampon.
The percent of drug release was thus calculated.
6. Release studies results:
Among the different formulations previously tested three versions were selected and compared under the new experimental conditions. These formulations differed in several parameters, i.e. the amount of drug per tampon, the type and amount of wetting agent, and the presence or absence of an HDPE substrate attached to the inner side of the formulated delivery system mounted on the tampons.
The selected formulations were as follows:
(a) 100 mg Ibuprofen* + 25% glycerol; split HDPE substrate (b) 100 mg Ibuprofen* + 10% Tween 80; split HDPE substrate (c) 100 mg Ibuprofen* + 10% Tween 80; continuous HDPE substrate (d) 150 mg Ibuprofen* + 20% glycerol + 20% PEG 1000; no HDPE
* amounts per tampon The release profiles of the different forinulated tampons, are presented in Figs. 7, 8 and 9.
The release profile of formulation number (a), under tight net enclosure conditions, is depicted in Fig. 7. It can clearly be observed, that most of the formulation is released within the first 2 hours. The release profiles of formulation numbers (b) and (c), shown in Fig. 8 clearly indicate that the use of Tween 80 as wetting agent instead of glycerol, does not increase the release rate and even slows it down. No significant difference in the release profiles was observed when using either split or continuous HDPE substrates.
Finally, it can be noted from Fig. 9 that the release profile of the drug from a tampon including glycerol and PEG- 1000 as wetting agents and no HDPE
substrate (formulation (d)) was markedly reduced. Only 50-60% of the drug was released within 120 minutes, as compared to the approximately 80% of the drug which were released within the same period of time when using an HDPE substrate (Fig. 7).
It is therefore suggested that the use of an HDPE substrate does promote and increase the rate of drug release.
Claims (16)
OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A transvaginal drug delivery system, comprising:
(a) a deposition comprising an effective amount of said drug and, optionally, a wetting agent; and (b) a woven or non-woven polymeric support on which said deposition is deposited, wherein said polymeric support is in the form of a strip.
(a) a deposition comprising an effective amount of said drug and, optionally, a wetting agent; and (b) a woven or non-woven polymeric support on which said deposition is deposited, wherein said polymeric support is in the form of a strip.
2. The delivery system according to claim 1, wherein said drug is selected from the group consisting of nonsteroidal anti-inflammatory drug (NSAID), anti-prostaglandin, prostaglandin inhibitor, COX-2 inhibitor, local anaesthetic, calcium channel blocker, potassium channel blocker, .beta.-adrenergic agonist, leukotriene blocking agent, smooth muscle inhibitor, vasodilator, hormone replacement drug, androgenic hormone and a drug capable of inhibiting dyskinetic muscle contraction.
3. The delivery system according to Claim 2, wherein said NSAID is selected from the group consisting of Aspirin, Ibuprofen, Indomethacin, Phenylbutazone, Bromfenac, Fenamate, Sulindac, Nabumetone, Ketorolac, and Naproxen; said local anesthetic selected from the group consisting of Lidocaine, Mepivacaine, Etidocaine, Bupivacaine, 2-Chloroprocaine hydrochloride, Procaine, and Tetracaine hydrochloride;
said calcium channel antagonist selected from the group consisting of Diltiazem, Israpidien, Nimodipine, Felodipine, Verapamil, Nifedipine, Nicardipine, and Bepridil;
said potassium channel blocker selected from the group consisting of Defetilide, E-4031, Almokalant, Sematilide, Ambasilide, Azimilide, Tedisamil, RP58866, sotalol, Piroxicam, and Ibutilide; said .beta.-adrenergic agonist selected from the group consisting of Terbutaline, Salbutamol, Metaproterenol, and Ritodrine; said vasodilator selected from the group consisting of nitroglycerin, isosorbide dinitrate and isosorbide mononitrate; said hormone replacement drug selected from the group consisting of estrogen or estradiol and progestogen; said androgenic hormone selected from the group consisting of testosterone and other androgenic hormones; said COX-2 inhibitor selected from the group consisting of Celecoxib, Meloxicam and Flosulide; and derivatives of the above drugs.
said calcium channel antagonist selected from the group consisting of Diltiazem, Israpidien, Nimodipine, Felodipine, Verapamil, Nifedipine, Nicardipine, and Bepridil;
said potassium channel blocker selected from the group consisting of Defetilide, E-4031, Almokalant, Sematilide, Ambasilide, Azimilide, Tedisamil, RP58866, sotalol, Piroxicam, and Ibutilide; said .beta.-adrenergic agonist selected from the group consisting of Terbutaline, Salbutamol, Metaproterenol, and Ritodrine; said vasodilator selected from the group consisting of nitroglycerin, isosorbide dinitrate and isosorbide mononitrate; said hormone replacement drug selected from the group consisting of estrogen or estradiol and progestogen; said androgenic hormone selected from the group consisting of testosterone and other androgenic hormones; said COX-2 inhibitor selected from the group consisting of Celecoxib, Meloxicam and Flosulide; and derivatives of the above drugs.
4. The delivery system according to Claim 3, wherein said NSAID is naproxen or ibuprofen.
5. The delivery system according to Claim 1, wherein the components of said deposition are dissolved in a solvent and the deposition is deposited by evaporation of said solvent.
6. The delivery system according to Claim 1, wherein said strip consists of at least one layer.
7. The delivery system according to Claim 6, wherein said strip consists of 2-16 layers.
8. A catamenial tampon for insertion in a human vagina, comprising:
(a) an inner core comprising an absorbent material;
(b) an outer layer comprising a liquid-permeable material; and (c) a delivery system according to Claim 1, wherein said delivery system is positioned between said inner core and said outer layer.
(a) an inner core comprising an absorbent material;
(b) an outer layer comprising a liquid-permeable material; and (c) a delivery system according to Claim 1, wherein said delivery system is positioned between said inner core and said outer layer.
9. The catamenial tampon according to Claim 8, further comprising a polymeric water-impermeable film between said delivery system and said inner core.
10. The catamenial tampon according to Claim 8, wherein said delivery system comprises a plurality of strips of the polymeric support.
11. The catamenial tampon according to Claim 10, comprising 3 strips.
12. The catamenial tampon according to Claim 8, further comprising a polymeric water-impermeable film behind said delivery system.
13. The catamenial tampon according to Claim 12, wherein said polymeric water-impermeable film comprises high-density polyethylene (HDPE).
14. Use of a catemenial tampon for transvaginal drug delivery which somprises inserting the tampon into a vagina, wherein said catamenial tampon comprises:
(a) an inner core comprising an absorbent material;
(b) an outer layer comprising a liquid-permeable material; and (c) a delivery system according to Claim 1, wherein said delivery system is positioned between said inner core and said outer layer.
(a) an inner core comprising an absorbent material;
(b) an outer layer comprising a liquid-permeable material; and (c) a delivery system according to Claim 1, wherein said delivery system is positioned between said inner core and said outer layer.
15. The use according to Claim 14, wherein said drug is a NSAID.
16. The use according to claim 15, wherein said NSAID is naproxen or ibuprofen.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2002/000528 WO2003070216A1 (en) | 2002-02-24 | 2002-02-24 | System for transvaginal drug delivery |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2477109A1 CA2477109A1 (en) | 2003-08-28 |
CA2477109C true CA2477109C (en) | 2010-11-16 |
Family
ID=27742202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2477109A Expired - Fee Related CA2477109C (en) | 2002-02-24 | 2002-02-24 | System for transvaginal drug delivery |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1478337A1 (en) |
JP (1) | JP4663237B2 (en) |
AU (1) | AU2002233588B2 (en) |
CA (1) | CA2477109C (en) |
IL (1) | IL163614A0 (en) |
WO (1) | WO2003070216A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100130907A1 (en) | 2008-11-21 | 2010-05-27 | Linkel Stephan M | Article of manufacture used in contact with human body surfaces |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4340055A (en) * | 1980-10-01 | 1982-07-20 | Sneider Vincent R | Impregnated tampon and method of fabricating same |
DE3928677C2 (en) * | 1989-08-30 | 1998-05-14 | Kimberly Clark Gmbh | Tampon for medical or hygienic purposes and process for its manufacture |
JPH0394218U (en) * | 1990-01-18 | 1991-09-26 | ||
JPH07450A (en) * | 1991-05-04 | 1995-01-06 | Mitsugi Takahashi | Sanitary tampon having suppository function |
US6197327B1 (en) * | 1997-06-11 | 2001-03-06 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
GB0009914D0 (en) * | 2000-04-20 | 2000-06-07 | Metris Therapeutics Limited | Device |
IL138183A0 (en) * | 2000-08-31 | 2001-10-31 | Rostam Ltd | Ph reducing formulation and delivery system for a tampon |
US6888043B2 (en) * | 2001-12-21 | 2005-05-03 | Kimberly-Clark Worldwide, Inc. | Feminine care products for the delivery of therapeutic substances |
-
2002
- 2002-02-24 JP JP2003569176A patent/JP4663237B2/en not_active Expired - Fee Related
- 2002-02-24 WO PCT/IB2002/000528 patent/WO2003070216A1/en active Application Filing
- 2002-02-24 EP EP02700512A patent/EP1478337A1/en not_active Withdrawn
- 2002-02-24 CA CA2477109A patent/CA2477109C/en not_active Expired - Fee Related
- 2002-02-24 IL IL16361402A patent/IL163614A0/en not_active IP Right Cessation
- 2002-02-24 AU AU2002233588A patent/AU2002233588B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2002233588B2 (en) | 2008-01-31 |
WO2003070216A1 (en) | 2003-08-28 |
AU2002233588A1 (en) | 2003-09-09 |
CA2477109A1 (en) | 2003-08-28 |
JP2005535563A (en) | 2005-11-24 |
IL163614A0 (en) | 2005-12-18 |
EP1478337A1 (en) | 2004-11-24 |
JP4663237B2 (en) | 2011-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7004171B2 (en) | System for transvaginal drug delivery | |
US6086909A (en) | Device and method for treatment of dysmenorrhea | |
EP1200151B1 (en) | Drug delivery device for insertion into the vagina, rectum or nasal cavity | |
US8388996B2 (en) | Methods of manufacturing a medicated tampon assembly | |
AU2005271865B2 (en) | Coated vaginal device for delivery of anti-migraine and anti-nausea drugs and a method for treatment of migraine and nausea | |
AU2002329842B2 (en) | Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy | |
Brannon-Peppas | Novel vaginal drug release applications | |
US20040043071A1 (en) | Intravaginal mucosal or transmucosal delivery of antimigraine and antinausea drugs | |
AU2002329842A1 (en) | Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy | |
Dobaria et al. | Vaginal drug delivery systems: a review of current status | |
CA2477109C (en) | System for transvaginal drug delivery | |
JPH05246841A (en) | Pharmaceutical preparation for topical application | |
MXPA99011480A (en) | Device and method for treatment of dysmenorrhea | |
NZ508130A (en) | Compositions in the manufacture of a medicament for treatment of dysmenorrhea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20180226 |